Alisertib, an ATP-competitive, orally available inhibitor of aurora A kinase (AAK), was well-tolerated, with responses observed in heavily pretreated patients with aggressive non-Hodgkin's lymphoma (NHL), including after autologous stem cell transplantation (ASCT), noted study investigators at the 53rd Annual Meeting and Exposition of American Society and Hematology.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.